Want to see SE:ALIF.B full AI Analyst Report?
Top Page
AddLife AB
(ALIF.B)
Select Model
Select Model
Rating:68Neutral
Price Target:
kr197.00
▲(21.23% Upside)
Action:Downgraded
Date:10/23/26
The score is driven primarily by improving financial performance (growing earnings and strong free cash flow) and supportive price momentum (trading above major moving averages with positive MACD). This is tempered by a demanding valuation (high P/E and low yield) and ongoing execution risks highlighted in the latest earnings call, including margin pressure in Medtech and elevated operating expenses despite management’s margin-expansion focus.
Positive Factors
Earnings and revenue growth
AddLife is combining organic and acquired growth with faster earnings expansion, indicating improving operating leverage and customer demand. Continued sales progress across Labtech and Medtech, alongside higher adjusted EBITA, can strengthen reinvestment capacity and support durable earnings development.
Negative Factors
Margin pressure
Despite higher earnings, lower EBIT and EBITDA margins show that cost, mix or investment pressures are limiting conversion of revenue into operating profit. Sustained margin pressure could reduce the benefit of growth and make management’s margin-expansion programs more important to future results.
Read all positive and negative factors
Positive Factors
Negative Factors
Earnings and revenue growth
AddLife is combining organic and acquired growth with faster earnings expansion, indicating improving operating leverage and customer demand. Continued sales progress across Labtech and Medtech, alongside higher adjusted EBITA, can strengthen reinvestment capacity and support durable earnings development.
Read all positive factors
AddLife AB (ALIF.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr22.23B
Dividend Yield0.82%
Average Volume (3M)178.49K
Price to Earnings (P/E)34.7
Beta (1Y)0.76
Revenue Growth1.62%
EPS Growth63.45%
CountrySE
Employees2,360
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)5.26
Shares Outstanding117,877,460
10 Day Avg. Volume329,309
30 Day Avg. Volume178,490
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)3.56
Price to Sales (P/S)1.86
P/FCF Ratio17.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.56
Revenue Forecast (FY)kr10.98B
AddLife AB Business Overview & Revenue Model
Company Description
AddLife AB (publ), a company established in 1906 and headquartered in Stockholm, Sweden, specializes in delivering cutting-edge equipment, medical apparatus, and chemical reagents. Its primary clientele includes the healthcare sector, academic and...
How the Company Makes Money
AddLife makes money mainly by selling and distributing life science and medtech products to healthcare providers and laboratories. Revenue is generated from (1) product sales of instruments/equipment (e.g., laboratory and diagnostic systems, medte...
AddLife AB Earnings Call Summary
Earnings Call Date:Oct 21, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Feb 03, 2027
Earnings Call Sentiment Positive
The call was strongly positive overall. Sales, adjusted EBITA, profit before tax, margins and operating cash flow all improved, Labtech performed particularly well, regional activity improved in the U.K. and Eastern Europe, and acquisition activity and the pipeline strengthened. The main challenges were the Medtech margin decline, unusually high operating expenses related to explicitly stated growth and acquisition activities, the ongoing dispute in Spain, seasonal softness, higher inventory and a foreign-exchange-driven increase in net debt.Positive Updates
Revenue Growth Across Organic and Acquired Operations
Third-quarter sales increased by 7%, comprising 4% organic growth and 3% acquired growth. Labtech delivered 2% organic growth following 9% organic growth in Q3 last year, while Medtech delivered 5% organic growth.
Negative Updates
Medtech Margin Decline
Medtech EBITA margin was 11.3%, down from 11.6% in the corresponding quarter last year. Management attributed the negative impact to lower summer activity, primarily in elective surgeries, together with resources being built for the increased share of advanced products.
Read all updates
Q3-2026 Updates
Positive
Negative
Revenue Growth Across Organic and Acquired Operations
Third-quarter sales increased by 7%, comprising 4% organic growth and 3% acquired growth. Labtech delivered 2% organic growth following 9% organic growth in Q3 last year, while Medtech delivered 5% organic growth.
Read all positive updates
Company Guidance
Management said margin expansion remains the top financial priority, with day-to-day efficiency measures, targeted programs, advanced products and acquisitions with high margins supporting future margin improvements; the share of revenue in the lower-left corner of its matrix was around 25% at the CMD 2 years ago, around 20% by end of '25, and is continuing to work on progressing, with the target of having everyone in the right-hand corner defined by a 10% EBITA margin and 45% profitable working cap. Management expects continued high acquisition activity going forward, more deals to be found through the organization, and said the pipeline looks quite good, while stating that it will continue to be picky.AddLife AB Financial Statement Overview
Summary
Income Statement
71
Positive
Balance Sheet
62
Positive
Cash Flow
68
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.70B | 10.44B | 10.29B | 9.69B | 9.08B | 7.99B |
| Gross Profit | 4.14B | 3.98B | 3.86B | 3.60B | 3.43B | 2.86B |
| EBITDA | 1.65B | 1.80B | 1.52B | 1.53B | 1.45B | 1.46B |
| Net Income | 644.00M | 560.00M | 252.00M | 190.00M | 480.00M | 719.00M |
Balance Sheet | ||||||
| Total Assets | 13.63B | 12.71B | 13.05B | 12.74B | 13.06B | 10.60B |
| Cash, Cash Equivalents and Short-Term Investments | 477.00M | 813.00M | 331.00M | 272.00M | 376.00M | 345.30M |
| Total Debt | 5.14B | 4.77B | 5.07B | 5.29B | 5.59B | 4.10B |
| Total Liabilities | 7.67B | 7.26B | 7.75B | 7.79B | 8.09B | 6.30B |
| Stockholders Equity | 5.95B | 5.44B | 5.31B | 4.96B | 4.97B | 4.29B |
Cash Flow | ||||||
| Free Cash Flow | 1.13B | 1.11B | 798.00M | 547.00M | 627.00M | 866.30M |
| Operating Cash Flow | 1.39B | 1.39B | 1.09B | 773.00M | 909.00M | 1.01B |
| Investing Cash Flow | -707.00M | -497.00M | -386.00M | -317.00M | -1.09B | -2.98B |
| Financing Cash Flow | -541.00M | -305.00M | -682.00M | -554.00M | 134.00M | 2.07B |
AddLife AB Technical Analysis
Positive
162.50
Price Trends
169.96
Positive
165.73
Positive
155.63
Positive
Market Momentum
3.97
Positive
59.15
Neutral
31.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ALIF.B, the sentiment is Positive. The current price of 162.5 is below the 20-day moving average (MA) of 177.95, below the 50-day MA of 169.96, and above the 200-day MA of 155.63, indicating a bullish trend. The MACD of 3.97 indicates Positive momentum. The RSI at 59.15 is Neutral, neither overbought nor oversold. The STOCH value of 31.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ALIF.B.
AddLife AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | kr4.67B | 33.84 | 15.23% | 1.41% | -1.64% | -14.61% | |
78 Outperform | kr2.23B | 23.18 | ― | 1.62% | 28.75% | 138.25% | |
70 Outperform | kr14.03B | 20.84 | 11.69% | 3.26% | -2.14% | -2.98% | |
68 Neutral | kr22.23B | 34.66 | 11.32% | 0.82% | 1.62% | 63.45% | |
66 Neutral | kr9.18B | 25.35 | 4.65% | 2.82% | -0.50% | -17.58% | |
53 Neutral | kr560.70M | 88.89 | 1.93% | ― | -0.51% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SE:ALIF.B
AddLife AB
182.30
-20.99
-10.32%
SE:ARJO.B
Arjo AB
33.72
4.59
15.77%
SE:CEVI
CellaVision AB
195.60
19.52
11.08%
SE:NOLA.B
Nolato AB
52.10
-8.58
-14.14%
SE:BACTI.B
Bactiguard Holding AB
16.00
-1.55
-8.83%
SE:STIL
Stille AB
248.50
68.00
37.67%
AddLife AB Corporate Events
AddLife boosts margins and ramps up acquisitions as Q3 earnings surge
Oct 21, 2026
AddLife reported third-quarter net sales of SEK 2,599 million, up 7 percent year-on-year, with organic growth of 4 percent after divestments and acquired growth of 3 percent. Both Labtech and Medtech contributed, with particularly strong momentum ...
AddLife buys German accessible-bathroom specialist LEHNEN GmbH
Oct 13, 2026
AddLife AB has expanded its Medtech business area by acquiring LEHNEN GmbH, a German family-owned manufacturer of stainless-steel products and system solutions for accessible and adapted bathrooms. LEHNEN, which has around EUR 5 million in sales a...
AddLife bolsters Labtech arm with acquisition of Portugal’s Unicam Sistemas Analíticos
Sep 9, 2026
AddLife AB has expanded its Labtech business area by acquiring Unicam Sistemas Analíticos, a leading Portuguese distributor of advanced analytical laboratory equipment with around EUR 10 million in annual revenue and 20 employees. The deal, w...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.